The target of the procurement is sera, urine or cerebrospinal fluid Protein fractions (-Prot-Fr), immunofixation (-Immfix), immunofixation daratumumab (S-DaraFix), AFOS isoenzymes (S-AFOS-Is) for determination, as well as reagents necessary for the detection of oligoclonal immunoglobulin G, oligoclonal (Li-IgG-Oc) and Beta-2-transferrin (Se-Likvo-O), calibrators, putty's own controls, rinsing, washing, staining and other solutions necessary for routine use equipment.
In addition, the Subscriber reserves an option to purchase 0-2 devices for HUS Diagnostic Center and 0-2 devices for ISLAB.
The customer also reserves an option to conclude a maintenance contract for the equipment used to perform the tests.
ISLAB will not participate in the service agreement option until 1.1.2024.
The contract period is valid for a fixed period of two (2) years, after which the contract continues until further notice.
The framework agreement for option devices is valid for four (4) years.
The products and services included in the procurement target will be procured for the clinical chemistry laboratory of the HUS Diagnostic Centre and the ISLAB Special Chemistry Laboratory as described in the invitation to tender and its appendices.
The object of the acquisition and its requirements are described in detail in the call for tender and its annexes.
The target of the procurement is sera, urine or cerebrospinal fluid Protein fractions (-Prot-Fr), immunofixation (-Immfix), immunofixation daratumumab (S-DaraFix), AFOS isoenzymes (S-AFOS-Is) for determination, as well as reagents necessary for the detection of oligoclonal immunoglobulin G, oligoclonal (Li-IgG-Oc) and Beta-2-transferrin (Se-Likvo-O), calibrators, putty's own controls, rinsing, washing, staining and other solutions necessary for routine use equipment.
The products and services included in the procurement target will be procured for the clinical chemistry laboratory of the HUS Diagnostic Centre and the ISLAB Special Chemistry Laboratory as described in the invitation to tender and its appendices.
In addition, the Subscriber reserves an option to purchase 0-2 devices for HUS Diagnostic Center and 0-2 devices for ISLAB.
The customer also reserves an option to conclude a maintenance contract for the equipment used to perform the tests.
ISLAB will not participate in the service agreement option until 1.1.2024.
The tests offered must be suitable for the analyzers existing in the Clinical Chemistry Laboratory of the HUS Diagnostic Center, as well as in the ISLAB Special Chemistry Laboratory (the existing equipment is described in Appendix 2 to the invitation to tender), or alternatively, the tenderer will provide both laboratories with suitable equipment specified in more detail in the invitation to tender and its appendices that meets the required capacity. If the tests are not suitable for existing equipment in the laboratory, the tenderer must include in its tender to the laboratories new equipment to replace these existing equipment, and offer the package on the basis of the principle of compensation for use. In this case, the provider does not charge for the use or maintenance of the equipment separately, but the equipment and its maintenance in accordance with the request for quotation are included in the given test price. Tests are paid for according to the ordered test putties. For the sake of clarity, it is stated that neither HUS nor ISLAB purchases equipment purchased through the compensation procedure, but the supplier retains ownership of it.
The maintenance that is the subject of the procurement concerns the analyzers with which the tests to be procured will be carried out.
If the test of the winning tender is suitable for existing analyzers in the laboratory, a contract in accordance with Annexes 3a and 3b to this invitation to tender and a maintenance contract in accordance with Annex 7 shall be concluded for the procurement.
If the winning tender includes replacement equipment, i.e. the tests are not suitable for existing equipment in the laboratory, the procurement will be carried out on the basis of the use compensation principle. In this case, the procurement shall be the subject of a compensation agreement in accordance with Annexes 4a and 4b to this invitation to tender.
A framework agreement is concluded for the equipment to be purchased as an option. The Subscriber purchases the equipment acquired through the framework agreement for its own ownership.
For the avoidance of doubt, even if the provider offers tests and new equipment to replace the old equipment on the basis of the compensation for use principle described above, any option devices will still be purchased separately. In other words, regardless of whether the procurement is subject to equipment contracts in accordance with Annexes 3a and 3b and a maintenance contract in accordance with Annex 7 or to compensation agreements for use in accordance with Annexes 4a and 4b, framework agreements on equipment in accordance with Annexes 6a and 6b are still concluded.
The estimated research volumes per year are as follows:
HUSLAB:
U -Prot-Fr, dU-Prot-Fr, Li-Prot-Fr: 2100
s -Mmfis, and -Mmmo, dU-Mmmo, Li-Mmfix: 3800
S -AFOS-Is: 1600
Li-IgG-Oc: 1600
Se-Likvo-O: 40
ISLAB:
U -Prot-Fr: 1300
S-Prot-Fr: 5100
S -Immfix, U -Immfix: 800
S -AFOS-Is: 750
Se-Likvo-O: 10
S-DaraFix: 85
The supplies contract is valid for a fixed period of two (2) years, after which the contract will continue until further notice.
The framework agreement for option devices is valid for four (4) years.
The Subscriber will select one (1) supplier with whom it will contract.